Edge Therapeutics Company Profile (NASDAQ:EDGE)

About Edge Therapeutics

Edge Therapeutics logoEdge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize, hospital-based therapies capable of transforming treatment paradigms in the management of life-threatening neurological and other conditions. Edge is evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). This study will evaluate EG-1962's ability to improve patient outcomes versus standard of care oral nimodipine after an aSAH resulting from a ruptured brain aneurysm. Edge's product candidates utilize Precisa, a platform with a approach that seeks to enable targeted and sustained drug exposure at the site of injury, while potentially avoiding off-target side effects associated with systemic delivery. Edge is also using its Precisa development platform to develop additional product candidates targeting other acute, serious conditions where limited or no current therapies exist.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EDGE
  • CUSIP:
Key Metrics:
  • Previous Close: $10.00
  • 50 Day Moving Average: $10.50
  • 200 Day Moving Average: $10.80
  • 52-Week Range: $6.52 - $13.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.27
  • P/E Growth: -0.08
  • Market Cap: $291.77M
  • Outstanding Shares: 28,917,000
  • Beta: 2.83
Profitability:
  • Return on Equity: -33.77%
  • Return on Assets: -30.43%
Debt:
  • Debt-to-Equity Ratio: 0.15%
  • Current Ratio: 26.62%
  • Quick Ratio: 26.62%
Additional Links:
Companies Related to Edge Therapeutics:

Analyst Ratings

Consensus Ratings for Edge Therapeutics (NASDAQ:EDGE) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.00 (98.22% upside)

Analysts' Ratings History for Edge Therapeutics (NASDAQ:EDGE)
Show:
DateFirmActionRatingPrice TargetDetails
5/9/2016Credit Suisse GroupLower Price TargetOutperform$19.00 -> $18.00View Rating Details
3/11/2016Leerink SwannReiterated RatingOutperform$27.00 -> $24.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$34.00 -> $18.00View Rating Details
10/26/2015GuggenheimInitiated CoverageBuy$30.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Edge Therapeutics (NASDAQ:EDGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017        
5/3/2016($0.34)($0.32)ViewListenView Earnings Details
3/8/2016Q4($0.32)($0.30)ViewListenView Earnings Details
11/6/2015Q315($0.23)($7.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Edge Therapeutics (NASDAQ:EDGE)
Current Year EPS Consensus Estimate: $-1.43 EPS
Next Year EPS Consensus Estimate: $-1.61 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.42)($0.42)($0.42)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.38)($0.38)($0.38)
Q4 20161($0.41)($0.41)($0.41)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Edge Therapeutics (NASDAQ:EDGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Edge Therapeutics (NASDAQ:EDGE)
Insider Ownership Percentage: 44.29%
Institutional Ownership Percentage: 49.25%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017Brian A LeuthnerInsiderSell1,500$9.52$14,280.00View SEC Filing  
2/6/2017Brian A LeuthnerInsiderSell3,000$9.61$28,830.00View SEC Filing  
2/2/2017Brian A LeuthnerInsiderSell3,000$9.50$28,500.00View SEC Filing  
12/1/2016Brian A LeuthnerInsiderSell7,500$11.60$87,000.00View SEC Filing  
10/3/2016Brian A LeuthnerInsiderSell7,500$10.25$76,875.00View SEC Filing  
8/8/2016W Bradford MiddlekauffVPBuy10,000$9.48$94,800.00View SEC Filing  
8/1/2016Brian A LeuthnerInsiderSell7,500$9.54$71,550.00View SEC Filing  
3/11/2016James HealyDirectorBuy541,343$7.30$3,951,803.90View SEC Filing  
10/6/2015Andrew J. EinhornCFOBuy45,000$11.00$495,000.00View SEC Filing  
10/6/2015James HealyDirectorBuy450,000$11.00$4,950,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Edge Therapeutics (NASDAQ:EDGE)
DateHeadline
News IconBerkeley Heights-based biotech names SVP, regulatory affairs (NASDAQ:EDGE)
www.njbiz.com - February 22 at 5:11 PM
feeds.benzinga.com logoEdge Therapeutics Appoints Alyssa Wyant as Senior Vice President, Regulatory Affairs and Makes Inducement Grant under NASDAQ Rule 5635(c)(4) (NASDAQ:EDGE)
feeds.benzinga.com - February 21 at 7:51 AM
News IconEdge Therapeutics Inc EDGE Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:EDGE)
www.bioportfolio.com - February 20 at 11:25 AM
einnews.com logoCanada's Enbridge post drop in profit, hurt by charges (NASDAQ:EDGE)
ethanol.einnews.com - February 18 at 9:52 AM
4-traders.com logoEdge Therapeutics : EG-1962 Data To Be Presented at International Stroke Conference 2017 (NASDAQ:EDGE)
www.4-traders.com - February 18 at 9:52 AM
finance.yahoo.com logoEdge Therapeutics’ EG-1962 Data To Be Presented at International Stroke Conference 2017 (NASDAQ:EDGE)
finance.yahoo.com - February 17 at 6:22 PM
finance.yahoo.com logoEdge Therapeutics to Present at Investor Conferences in February (NASDAQ:EDGE)
finance.yahoo.com - February 8 at 5:24 PM
News IconGalectin Therapeutics Presentation Now Available for On-Demand Viewing (NASDAQ:EDGE)
www.kait8.com - February 6 at 9:03 AM
businesswire.com logoVividion Therapeutics, Inc., Launches With $50 Million Series A Financing (NASDAQ:EDGE)
www.businesswire.com - February 2 at 10:23 PM
openpr.com logoAneurysmal Subarachnoid Hemorrhage Market : The report is an all-important tool to understand the progression by 2025 (NASDAQ:EDGE)
www.openpr.com - February 2 at 3:32 AM
News IconRSI Update on Shares of Edge Therapeutics Inc. (EDGE) - Sherwood Daily (NASDAQ:EDGE)
sherwooddaily.com - January 31 at 4:26 AM
News IconStock Watch: Focusing in on Edge Therapeutics, Inc. (NASDAQ:EDGE) - The Tribune (NASDAQ:EDGE)
lakecitytribune.com - January 31 at 4:26 AM
News IconAutologous Cell Therapy Market Is Expected to Be Worth Us$23.7 Bn by the End of 2024 (NASDAQ:EDGE)
www.medgadget.com - January 30 at 11:25 PM
sbwire.com logoAneurysmal Subarachnoid Hemorrhage Market Deep Research Study with Forecast by 2025 (NASDAQ:EDGE)
www.sbwire.com - January 30 at 12:28 PM
News IconFollowing FCF Scores for Edge Therapeutics, Inc. (NASDAQ:EDGE) - The Tribune (NASDAQ:EDGE)
lakecitytribune.com - January 27 at 6:33 PM
streetinsider.com logoForm 4 Edge Therapeutics, Inc. For: Jan 23 Filed by: Macdonald R. Loch - StreetInsider.com (NASDAQ:EDGE)
www.streetinsider.com - January 26 at 6:11 PM
News IconThe report is an all-important tool to understand the progression of the Aneurysmal Subarachnoid Hemorrhage Market, 2017 – 2025 (NASDAQ:EDGE)
empowerednews.net - January 25 at 11:10 PM
News IconTechnical Buzz on Edge Therapeutics, Inc. (NASDAQ:EDGE) - The Tribune (NASDAQ:EDGE)
lakecitytribune.com - January 24 at 3:16 AM
News IconEquity Research Analysts Peer Into Their Crystal Ball For Edge Therapeutics, Inc. (:EDGE) - Aiken Advocate (NASDAQ:EDGE)
aikenadvocate.com - January 21 at 4:11 AM
News IconObalon Therapeutics, Inc. to Ring The Nasdaq Stock Market Closing Bell (NASDAQ:EDGE)
forextv.com - January 19 at 6:16 PM
News IconIntarcia Therapeutics Teams Up With Gates Foundation on Chronic Health Issues Like HIV (NASDAQ:EDGE)
www.edgemedianetwork.com - January 18 at 5:17 PM
News IconEdge Therapeutics Inc EDGE Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:EDGE)
www.bioportfolio.com - January 12 at 10:22 PM
globenewswire.com logoIntellia Therapeutics Joins Genomics England’s Industry Consortium (NASDAQ:EDGE)
www.globenewswire.com - January 11 at 5:26 PM
prnewswire.com logoGenVec to Present at Phacilitate Cell & Gene Therapy World 2017 (NASDAQ:EDGE)
www.prnewswire.com - January 11 at 5:26 PM
marketexclusive.com logoJuno Therapeutics, Inc. (NASDAQ:JUNO) Files An 8-K Regulation FD Disclosure (NASDAQ:EDGE)
marketexclusive.com - January 10 at 3:44 AM
News Icon(NASDAQ:EDGE) Receives An Update From Brokers (NASDAQ:EDGE)
vouxmagazine.com - December 30 at 5:18 PM
marketexclusive.com logoEcho Therapeutics, Inc. (NASDAQ:ECTE) Files An 8-K Other Events (NASDAQ:EDGE)
marketexclusive.com - December 27 at 5:03 PM
News IconGrowth Story Unfolding for Edge Therapeutics, Inc. (:EDGE) - Prospect Journal (NASDAQ:EDGE)
prospectjournal.com - December 27 at 11:50 AM
insidermonkey.com logoIs Osiris Therapeutics, Inc. (OSIR) A Good Stock To Buy? (NASDAQ:EDGE)
www.insidermonkey.com - December 18 at 10:00 PM
capitalcube.com logoEdge Therapeutics, Inc. :EDGE-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016 (NASDAQ:EDGE)
www.capitalcube.com - December 15 at 5:28 PM
News IconCan This Stock Gain Traction: Edge Therapeutics, Inc. (:EDGE) - Prospect Journal (NASDAQ:EDGE)
prospectjournal.com - December 13 at 11:15 AM
News IconNew report: Brain hemorrhage pipeline market review and therapeutic development for H2 2016 (NASDAQ:EDGE)
www.whatech.com - December 12 at 5:05 PM
News IconUpdate on Valuation Formula's For Edge Therapeutics, Inc. (NASDAQ:EDGE) - The Business Journal (NASDAQ:EDGE)
belmontbusinessjournal.com - December 12 at 11:55 AM
insidermonkey.com logoHedge Funds Aren’t Crazy About Aimmune Therapeutics Inc (AIMT) Anymore (NASDAQ:EDGE)
www.insidermonkey.com - December 11 at 11:10 AM
News IconBrain Hemorrhage Market Report Overview, Development and Comparative Analysis 2016 (NASDAQ:EDGE)
empowerednews.net - December 10 at 4:45 PM
globenewswire.com logoEdge Therapeutics Announces Publication of Phase 1/2 Data on EG ... - GlobeNewswire (press release) (NASDAQ:EDGE)
globenewswire.com - December 9 at 5:09 PM
finance.yahoo.com logo9:18 am Edge Therapeutics announces publication of results from its Phase 1/2 clinical study of EG-1962 online at Stroke (NASDAQ:EDGE)
finance.yahoo.com - December 9 at 5:09 PM
finance.yahoo.com logoEdge Therapeutics Announces Publication of Phase 1/2 Data on EG-1962 for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Peer-Reviewed Medical Journal, Stroke (NASDAQ:EDGE)
finance.yahoo.com - December 9 at 5:09 PM
News IconForge Therapeutics and Evotec Form Strategic 'Superbug' Alliance (NASDAQ:EDGE)
www.kswo.com - December 9 at 8:03 AM
businesswire.com logoEvotec and Forge Therapeutics Form Strategic 'Superbug' Alliance (NASDAQ:EDGE)
www.businesswire.com - December 9 at 8:03 AM
News IconEx-Insys executives arrested for bribing U.S. doctors to prescribe painkiller (NASDAQ:EDGE)
www.metro.us - December 8 at 10:34 PM
nasdaq.com logoEuropean ADRs Edge Lower as Manufacturers Post Mixed Fortunes (NASDAQ:EDGE)
www.nasdaq.com - December 8 at 10:34 PM
News IconGlobal Kidney Function Tests Market: Size, Share, Growth, Segments, Industry Analysis and Forecasts 2015 – 2021 (NASDAQ:EDGE)
qwtjlive.com - December 8 at 9:16 AM
News IconJoin the Premier Gathering of Senior-Level Executives: Early Bird Rate Ends Friday (NASDAQ:EDGE)
www.pharmiweb.com - December 8 at 9:16 AM
prnewswire.com logoLeading Edge, Revolutionary Controlled Growing Technology For Cannabis & Agricultural Projects Boosts Revenue Growth (NASDAQ:EDGE)
www.prnewswire.com - December 8 at 9:16 AM
News IconShares Ticking Lower in Trade: Edge Therapeutics, Inc. (:EDGE) - Prospect Journal (NASDAQ:EDGE)
prospectjournal.com - December 7 at 5:20 PM
News IconTenaya Therapeutics launches with the goal of curing heart disease (NASDAQ:EDGE)
scienmag.com - December 6 at 5:05 PM
tmcnet.com logoIntellia Therapeutics Opens New Headquarters as Company Continues to Advance CRISPR/Cas9 Platform and Pipeline (NASDAQ:EDGE)
www.tmcnet.com - December 1 at 4:58 PM
News IconStock Climbing Higher Over Past Half Year: Edge Therapeutics, Inc. (:EDGE) - CSZ News (NASDAQ:EDGE)
cincysportszone.com - November 21 at 10:44 PM
News IconInvestor Monitor: Narrowing in on Edge Therapeutics, Inc. (NASDAQ:EDGE) - Wall Street Lion (NASDAQ:EDGE)
wslnews.com - November 21 at 10:44 PM

Social

What is Edge Therapeutics' stock symbol?

Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE."

Where is Edge Therapeutics' stock going? Where will Edge Therapeutics' stock price be in 2017?

3 analysts have issued 12-month price objectives for Edge Therapeutics' stock. Their forecasts range from $18.00 to $24.00. On average, they anticipate Edge Therapeutics' stock price to reach $20.00 in the next year.

When will Edge Therapeutics announce their earnings?

Edge Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

Who owns Edge Therapeutics stock?

Edge Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (8.73%), New Leaf Venture Partners L.L.C. (8.11%), Janus Capital Management LLC (7.48%), Acuta Capital Partners LLC (3.60%), Opaleye Management Inc. (0.97%) and FMR LLC (0.72%). Company insiders that own Edge Therapeutics stock include Andrew J Einhorn, Brian A Leuthner, James Healy and W Bradford Middlekauff.

Who sold Edge Therapeutics stock? Who is selling Edge Therapeutics stock?

Edge Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC.

Who bought Edge Therapeutics stock? Who is buying Edge Therapeutics stock?

Edge Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including New Leaf Venture Partners L.L.C., Acuta Capital Partners LLC, Franklin Resources Inc. and State Street Corp. Company insiders that have bought Edge Therapeutics stock in the last two years include Andrew J Einhorn, James Healy and W Bradford Middlekauff.

How do I buy Edge Therapeutics stock?

Shares of Edge Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Edge Therapeutics stock cost?

One share of Edge Therapeutics stock can currently be purchased for approximately $10.09.

Edge Therapeutics (NASDAQ:EDGE) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Earnings History Chart

Earnings by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Dividend History Chart

Dividend Payments by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Last Updated on 2/25/2017 by MarketBeat.com Staff